Billing and Coding Guide. Hospital Outpatient Department

Similar documents
Summary of Package Insert 1

CODING AND REIMBURSEMENT GUIDE

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

SAMPLE CLAIM FORMS FOR SPINRAZA

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Oregon Individual and Family Plans OREGON APPLICATION AND STANDARD HEALTH STATEMENT

Supplementary Online Content

Prime Enrollees Consumer Watch NHC Patuxent River FY 2016 Defense Health Cost Assessment & Program Evaluation

Invasive Pneumococcal Disease Quarterly Report. July September 2017

Diabetes affects 29 million Americans, imposing a substantial

Invasive Pneumococcal Disease Quarterly Report July September 2018

Agilent G6825AA MassHunter Pathways to PCDL Software Quick Start Guide

Seasonal influenza vaccination programme country profile: Ireland

For Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Billing for Xofigo (radium Ra 223 dichloride) Injection and Administration in Separate Sites of Care

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

TAKE CONTROL HIGH LEVEL

Submitting a Statement of Medical Necessity (SMN) for Humatrope (somatropin for injection)

5 WAYS VCARE? What is GLAUCOMA. has earned the highest MEDICAID? Are you on. Are you at Risk? Viva Medicare Plus. to Avoid Hospital Readmissions

Welcome to our Practice

First-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)

Whangarei District Council Class 4 Gambling Venue Policy

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

IMPORTANT Reminders for Patients. IMPORTANT Information for Doctors/Nurses

Using Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids

How Do Emergency Physicians Interpret Prescription Narcotic History When Assessing Patients Presenting to the Emergency Department with Pain?

A Four-System Comparison of Patients With Chronic Illness: The Military Health System, Veterans Health Administration, Medicaid, and Commercial Plans

Patient Identification. a Yes. a No. Patient: First. Last. Address: Street. Apt. State. City. Zip. Date of Birth: Weight: Age: Race:

P AND K IN POTATOES. Donald A Horneck Oregon State University Extension Service

Input from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer

ULTOMIRIS is administered once every 8 weeks a

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

Patient Monitoring Checklist

build Firm, sexy arms

Metabolic syndrome (MetS) is defined by a group

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)

Optimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality

Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California,

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Factor XIII Deficiency (Fibrin Stabilizing Factor Deficiency)

Defining and Measuring Chronic Conditions: Imperatives for Research, Policy, Program, and Practice

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

THE 2017 GENENTECH ONCOLOGY TREND REPORT

YERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011

key words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization

May 28, Congressional Requesters

Effects of physical exercise on working memory and prefrontal cortex function in post-stroke patients

BOTOX Billing and Coding for Chronic Migraine

Chapter 5: The peripheral nervous system Learning activity suggested answers

This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled.

Provide a Buffet and Carvery Service

For Adults with Metastatic Melanoma

Product Monograph. Published by

EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

Bioactive milk components to secure growth and gut development in preterm pigs ESTER ARÉVALO SUREDA PIGUTNET FA1401 STSM

Urinary Tract Infection in Women

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary

HIGHLIGHTS OF PRESCRIBING INFORMATION

JOB DESCRIPTION. Volunteer Student Teacher. Warwick in Africa Programme. Warwick in Africa Programme Director

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

Immune-Mediated Adverse Reactions Management Guide

Urinary Tract Infection in Men

Coding and Reimbursement Guide

(Received for publication February 17, 1944) Since, as has been demonstrated by Enders (3),

SOME MECHANISTIC CONCEPTS IN ELECTROPHILIC ADDITION REACTIONS TO C=C BONDS

Weight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000

HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998

2.3. with type 1 diabetes <3 years of age. (8.4)

Chronic obstructive pulmonary disease (COPD) is the third

The Prevalence of Bacteremia in Pediatric Patients With Community-Acquired Pneumonia: Guidelines to Reduce the Frequency of Obtaining Blood Cultures

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:

STEPS SIMPLE TO INTRODUCE ONCE-DAILY THERAPY TO YOUR ADULT PATIENTS WITH TYPE 2 DIABETES START THE CONVERSATION WITH LOOK INSIDE TO FIND OUT HOW

THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS

DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION

Finite-Dimensional Linear Algebra Errata for the first printing

2 Comprehensive Child Crisis Services

1 Indications and Usage

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

Product Monograph INDICATIONS AND USAGE IMPORTANT RISK INFORMATION WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY

These highlights do not include all the information needed to use ADVATE safely and effectively. See full prescribing information for ADVATE.

Estimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States

Check your understanding 3

Olanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study

FULL PRESCRIBING INFORMATION

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population

Arthroscopic Anatomy of Shoulder

See 17 for PATIENT COUNSELING INFORMATION. Revised: 01/2018 FULL PRESCRIBING INFORMATION: CONTENTS*

BENIGN ulceration along the greater curvature of the pars media of the

Relationship Between Hospital Performance on a Patient Satisfaction Survey and Surgical Quality

Restorative planning for hemisection surgery: a technique report

Diabetes is a chronic and highly prevalent condition that

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE

Coding and Reimbursement Guide

Discuss IBS-D with your doctor

Transcription:

illing nd oding Guide Hospitl Outptient Deprtment

overge, coding, nd pyment in the hospitl outptient deprtment ONPTTRO (ptisirn) received US Food nd Drug dministrtion (FD) pprovl on 10 ug 2018, nd is indicted for the tretment of the polyneuropthy of hereditry trnsthyretin-medited myloidosis in dults. overge For Medicre ptients receiving ONPTTRO who re covered under Medicre Prt enefit, the Medicre dministrtive ontrctors (Ms) my require dditionl chrt documenttion to determine the medicl necessity of the tretment, lthough prior uthoriztion is not required For ptients enrolled in Stte Medicid or commercil helth pln, ONPTTRO coverge will vry y pyer Pyment Medicre Pyer Type Stte Medicid nd ommercil Pyers Pyment Methodology 95% of verge Wholesle Price (WP) Pyment rtes will vry y pyer nd provider contrct It is lwys the provider s responsiility to determine the pproprite helthcre setting nd to sumit true nd correct clims for products nd services rendered. Providers should contct third-prty pyers for specific informtion on their coding, coverge, nd pyment policies. Medicre reimursement for ONPTTRO in the physicin office will vry in its first yer on the mrket. The rte listed is pplicle during the immedite post-lunch period nd is suject to chnge. Due to the implementtion of the 21st entury ures ct, some HOPDs, especilly off-cmpus sites, my e reimursed sed on the wholesle cquisition cost (W) + 6% methodology. Once n verge selling price (SP) hs een estlished, the Medicre pyment for ONPTTRO will e SP + 6%. full 2 qurters of sles dt re required efore n SP cn e estlished. lnylm Field Reimursement Directors re ville to meet with you nd your stff to nswer ny reimursement-relted questions out ONPTTRO. ontct lnylm ssist t 1-833-256-2748. Plese see Importnt Sfety Informtion on the following pges nd ccompnying Full Prescriing Informtion. 2

oding Plese refer to the tle elow to support pproprite clims sumission for ONPTTRO. ode Type ode ode Description ID-10-M E85.1 Neuropthic heredofmilil myloidosis PT c,d HPS e (Medicre, Medicid, or ommercil Pyers) 96365 +96366 +96367 96379 96413 +96415 9399 J3490 J1094 J1200 J2780 Intrvenous infusion, for therpy, prophylxis, or dignosis (specify sustnce or drug); initil, up to 1 hour Intrvenous infusion, for therpy, prophylxis, or dignosis (specify sustnce or drug); ech dditionl hour Intrvenous infusion, for therpy, prophylxis, or dignosis (specify sustnce or drug); dditionl sequentil infusion of new drug/sustnce, up to 1 hour Unlisted therpeutic, prophylctic, or dignostic intrvenous or intr-rteril injection or infusion hemotherpy dministrtion, intrvenous infusion technique; up to 1 hour, single or initil sustnce/drug hemotherpy dministrtion, intrvenous infusion technique; ech dditionl hour Unclssified drugs or iologicls Unclssified drugs Dexmethsone f Diphenhydrmine f Rnitidine f 0250 Generl phrmcy Revenue 0260 Intrvenous therpy 0636 Drugs requiring detiled coding ND g 10-digit: 71336-1000-1 11-digit: 71336-1000-01 10 mg/5 ml (2 mg/ml) single-dose vil c PT 2014 mericn Medicl ssocition. ll rights reserved. d One-hour code covers up to 90 minutes. e lims sumitted with miscellneous code 9399 should include product nme, route of dministrtion, nd dosge in ml nd ND (ND 71336-1000-01) in Loctor 80 on the U-04 clim form. Providers should contct commercil pyers nd Stte Medicid gencies for specific informtion on reporting drugs using miscellneous HPS codes. f For premedictions not ville or not tolerted intrvenously, equivlents my e dministered orlly. g Given ll the different possile sources for J1094, J1200, nd J2780 NDs s well s different HPS codes for premeds, plese consult with your Field Reimursement Director or the mnufcturers for the pplicle ND nd HPS codes. ID-10-M=Interntionl lssifiction of Diseses, 10th Revision, linicl Modifiction; PT=urrent Procedurl Terminology; HPS=Helthcre ommon Procedure oding System; ND=Ntionl Drug ode.

Hospitl outptient: smple U-04 clim form ONPTTRO (ptisirn) nd the ssocited services provided in hospitl outptient setting re illed on the U-04 clim form or its electronic equivlent. smple U-04 clim form for illing ONPTTRO is provided on the next pge. The following U-04 clim form for ONPTTRO is for illustrtive purposes It is the provider s responsiility to determine the pproprite helthcre setting nd to sumit true nd correct clims for the products nd services rendered Providers should contct pyers for specific informtion on their coding, coverge, nd pyment policies Some pyers my require the use of JW modifier when illing for the unused portion of the single-dose vil (wstge) providers should contct pyers out specific coding nd pyment policies Providers should contct their illing softwre vendors to ensure they re utilizing the recommended loops nd segments Dosing clcultion exmple ONPTTRO is supplied s 10 mg/5 ml (2 mg/ml) solution in single-dose vil The recommended dose of ONPTTRO is 0.3 mg/kg dministered vi n 80-minute intrvenous (IV) infusion once every 3 weeks Dosing is sed on ctul ody weight. For ptients weighing 100 kg, the recommended dose is 30 mg lcultion How to clculte mg (ody weight (kg) x 0.3 mg/kg) = mg How to clculte ml (mg x 5 ml/10 mg) = ml Proper preprtion of ONPTTRO requires filtrtion to remove prticultes. n dditionl vil my e required depending on the type of filter used nd the mount of product tht remins in the filter (hold-up volume). The clcultor found in the ONPTTRO Dosing & dministrtion Guide ssumes tht 1 ml of drug product remins in the filter when determining the numer of vils needed. Exmple - 68 kg ptient mg ml 68 kg x 0.3 mg/kg = 20.4 mg 20.4 mg x 5 ml/10 mg = 10.2 ml Plese see Importnt Sfety Informtion on the following pges nd ccompnying Full Prescriing Informtion. 4

LOTOR 42 List the pproprite revenue code for the service provided. For Medicre, use the revenue code 0636 Drugs requiring detiled coding. For pyers other thn Medicre, the revenue code for ONPTTRO my vry, lthough some privte pyers nd Medicid plns ccept revenue code 0250 Generl phrmcy. 1 2 3 4 5 6 7 1 2 3 PT. 4 TYPE NTL # OF ILL. MED. RE. # 8 PTIENT NME 10 IRTHDTE 11 SEX DMISSION 12 DTE 13 HR 14 TYPE 15 SR Smple U-04 lim Form 16 DHR 9 PTIENT DDRESS c d 5 FED. TX NO. 6 STTEMENT OVERS PERIOD FROM THROUGH c d 17 STT 18 19 20 ONDITION ODES 24 21 25 23 27 22 26 28 29 DT 30 STTE 31 OURRENE 32 OURRENE 33 OURRENE 34 OURRENE 35 OURRENE SPN 36 OURRENE SPN 37 ODE DTE ODE DTE ODE DTE ODE DTE ODE FROM THROUGH ODE FROM THROUGH 38 39 40 41 VLUE ODES VLUE ODES VLUE ODES ODE MOUNT ODE MOUNT ODE MOUNT 42 REV. D. 43 DESRIPTION 44 HPS / RTE / HIPPS ODE 45 SERV. DTE 46 SERV. UNITS 47 TOTL HRGES 48 NON-OVERED HRGES 49 7 e 1 2 3 4 5 6 7 LOTOR 40 There re 3 different scenrios for PT codes (listed elow). For ech, the first clim line should lwys e for ONPTTRO with J3490 followed y the premed HPS codes. 1. 96365/96366 nd 96367 comintion 2. 96413/96415 nd 96367 comintion 3. 96379 scenrio LOTOR 45 Enter the service dte. 8 8 9 9 LOTOR 43 Enter the corresponding description for the revenue code listed in Loctor 42. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 PGE OF RETION DTE TOTLS 52 REL. 53 SG. INFO EN. 50 PYER NME 51 HELTH PLN ID 54 PRIOR PYMENTS 55 EST. MOUNT DUE 56 NPI 57 OTHER PRV ID 58 INSURED S NME 59 P.REL 60 INSURED S UNIQUE ID 61 GROUP NME 62 INSURNE GROUP NO. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 LOTOR 46 Enter the numer of service units for ech line item. LOTOR 47 Enter the totl chrge for ech line item. LOTOR 44 Enter the pproprite HPS code. For Medicre: 9399 Unclssified drugs nd iologics For Medicid nd ommercil Pyers: J3490 Unclssified drugs 63 TRETMENT UTHORIZTION ODES 66 DX 67 D E F G H I J K L M N O P Q 69 DMIT 70 PTIENT 71 PPS 72 73 DX RESON DX c ODE EI c 74 PRINIPL PROEDURE. OTHER PROEDURE. OTHER PROEDURE 75 ODE DTE ODE DTE ODE DTE 76 TTENDING NPI QUL c. d. OTHER PROEDURE OTHER PROEDURE ODE DTE ODE DTE 80 REMRKS U-04 MS-1450 PPROVED OM NO. 0938-0997 81 e. OTHER PROEDURE ODE DTE LST FIRST c 64 DOUMENT ONTROL NUMER 65 EMPLOYER NME 77 OPERTING 78 OTHER 79 OTHER d LST FIRST Ntionl Uniform NU illing ommittee LST LST NPI NPI NPI FIRST QUL FIRST QUL QUL THE ERTIFITIONS ON THE REVERSE PPLY TO THIS ILL ND RE MDE PRT HEREOF. 68 LOTOR 66 Enter 0 to indicte use of the ID-10-M dignosis coding system. LOTOR 67 Enter the primry dignosis code. LOTOR 80 Until permnent HPS code for ONPTTRO is issued, enter the product nme, route of dministrtion, dosge in ml (refer to exmple on the left to find out how to clculte dosing), nd ND (ND 71336-1000-01). onfirm with the pyer whether dditionl informtion is required in this field (e.g., wstge, invoice price, strength in mg/ml).

Loop nd segment guide Importnt considertions when including ND informtion long with unlisted codes on your U-04 clims Medicre nd commercil insurers require tht dditionl informtion e included on your clims when illing NDs, especilly when the corresponding HPS code is Not Otherwise lssified (NO) code like 9399 (Medicre) or J3490 (commercil insurers). In ddition, some pyers my lso require tht unlisted PT code 96379 e used to report n ONPTTRO (ptisirn) infusion. The tle elow is quick loop nd segment reference guide when illing your U-04 clims electroniclly. Plese e sure to contct your pyers to inquire out dditionl informtion tht my e required. Informtion ode(s) or dditionl Informtion U-04 Loctor Electronic Loop Equivlent Segment HPS or PT ode For Medicre: 9399 nd/or 96379 For Medicid nd ommercil Pyers: J3490 nd/or 96379 Loctor 44 2400 SV-202-2 Unlisted PT ode Descriptor ONPTTRO IV, ND 71336-1000-01, XmL dose, Xmg strength c Loctor 44 2400 SV202-7 PT ode(s) 96365/96366/96367 96413/96415/96367 Loctor 44 2400 SV202-2 HPS Level II ode Units 1 Loctor 46 2400 SV205 dditionl Product Informtion ONPTTRO IV, ND 71336-1000-01, XmL dose, Xmg strength c Loctor 80 2300 NTE01 nd NTE02 ID-10-M ode (primry) E85.1 Loctor 67 2400 HI01-2 ill Type ode Provide specific Loctor 4 2300 LM05-1 Revenue ode(s) 0250 0260 0636 Other revenue codes my pply, s pproprite Loctor 42 2400 SV201 ND Identifier N4 Loctor 43 2410 LIN02 ND Numer 71336-1000-01 Loctor 43 2410 LIN03 Quntity/Dosge (Numer of ND units) sed on ptient weight. Refer to ONPTTRO dosing clcultion exmple on pge 4 Loctor 43 2410 TP04 Unit of Mesure ml Loctor 43 2410 TP05-1 When required. Pyers my prefer tht unlisted PT ode nd NO descriptors e included in one loop/segment comintion over nother. Including ONPTTRO IV, ND 71336-1000-01, XmL dose, Xmg strength in oth sections of your electronic clims is cceptle nd ensures you re sumitting this importnt informtion to your pyers. c The recommended dose of ONPTTRO is 0.3 mg/kg. For ptients weighing 100 kg, the recommended dose is 30 mg. Plese see Importnt Sfety Informtion on the following pges nd ccompnying Full Prescriing Informtion. 6

len clim filing checklist Select the pproprite primry dignosis onfirm pproprite clinicl documenttion to support dignosis Understnd ny pyer-specific requirements (prior uthoriztion, coding detils, etc.) Utilize ll pproprite ID-10, PT, HPS nd Revenue codes For Medicre clims in the hospitl outptient deprtment (HOPD), use 9399 s the miscellneous HPS code Rememer: illing Unit = 1 In generl, ll other clims (non-medicre pyers nd Medicre physicin office) use the miscellneous code J3490 (Unclssified drugs) If using miscellneous code, mke sure Loctor 80 d (U-04) is unlocked nd ville for use within the illing softwre Properly document the 11-digit ND, product nme, route of dministrtion, nd dosge in ml (see pge 4 for exmple of dosing clcultion) Rememer to use the smple clim form on pge 5 s guide nticipte requests from pyers for dditionl clinicl informtion prior to clims eing processed for pyment lnylm Field Reimursement Directors re ville to help nswer ny reimursement-relted questions you my hve out ONPTTRO. ontct lnylm ssist t 1-833-256-2748. d It is lwys the provider s responsiility to determine the pproprite helthcre setting nd to sumit true nd correct clims for those products nd services rendered. ontct third-prty pyers for specific informtion on their coding nd pyment policies.

8m 7pm ET, Mondy Fridy : 1-833-256-2748 : 1-833-256-2747 To lern more out ONPTTRO, visit www.onpttro.com. Indiction ONPTTRO (ptisirn) is indicted for the tretment of the polyneuropthy of hereditry trnsthyretinmedited myloidosis in dults. Importnt Sfety Informtion Infusion-Relted Rections Infusion-relted rections (IRRs) hve een oserved in ptients treted with ONPTTRO. In controlled clinicl study, 19% of ONPTTRO-treted ptients experienced IRRs, compred to 9% of plceo-treted ptients. The most common symptoms of IRRs with ONPTTRO were flushing, ck pin, nuse, dominl pin, dyspne, nd hedche. To reduce the risk of IRRs, ptients should receive premediction with corticosteroid, cetminophen, nd ntihistmines (H1 nd H2 lockers) t lest 60 minutes prior to ONPTTRO infusion. Monitor ptients during the infusion for signs nd symptoms of IRRs. If n IRR occurs, consider slowing or interrupting the infusion nd instituting medicl mngement s cliniclly indicted. If the infusion is interrupted, consider resuming t slower infusion rte only if symptoms hve resolved. In the cse of serious or life-thretening IRR, the infusion should e discontinued nd not resumed. Reduced Serum Vitmin Levels nd Recommended Supplementtion ONPTTRO tretment leds to decrese in serum vitmin levels. Supplementtion t the recommended dily llownce (RD) of vitmin is dvised for ptients tking ONPTTRO. Higher doses thn the RD should not e given to try to chieve norml serum vitmin levels during tretment with ONPTTRO, s serum levels do not reflect the totl vitmin in the ody. Ptients should e referred to n ophthlmologist if they develop oculr symptoms suggestive of vitmin deficiency (e.g. night lindness). dverse Rections The most common dverse rections tht occurred in ptients treted with ONPTTRO were upper respirtory trct infections (29%) nd infusion relted rections (19%). Plese see ccompnying Full Prescriing Informtion for dditionl informtion. ONPTTRO nd lnylm ssist re trdemrks of lnylm Phrmceuticls, Inc. 2018 lnylm Phrmceuticls, Inc. ll rights reserved. TTR02-US-00077-032018